Wales is a self-governing country of the UK and the Welsh Government is the devolved Government for Wales. The Welsh Government’s decision-making powers within a small and joined-up country mean we can act fast. They also mean we are responsible for our own economic development, so you won’t find a more pro-business Government anywhere. Wales has a strong industrial heritage that has shaped our confident, creative and ambitious economy of today. Wales means business.
Trialmed
Trialmed is the trusted clinical trial partner for patients, trial volunteers and sponsors/CROs. We facilitate clinical research as a care option for patients and healthy volunteers as a part of their health care journey. We create holistic experiences that put the patient first through our welcoming clinics, user-friendly digital technology, and our relentless focus on total quality delivery. Our patient-first approach makes Trialmed the clinical research destination of choice for patients and healthy volunteers. With extensive access to patients in the geographies where we operate, Trialmed ensures reliable enrollment outcomes that consistently meet or exceed sponsor expectations. We offer Home Trial Services for the ultimate in patient flexibility — conducting clinical trial visits where the patient prefers, such as the patient’s home, office or school. Our flexible clinical trial solutions scale to the sponsor’s needs and budget, offering a best-in-class early development services and site network from Phase I-IV.
The National Institute for Health and Care Research (NIHR)
The NIHR Life Sciences Industry Hub is your entry point to England’s integrated clinical research system, with coordinated access to UK-wide capability. The Industry Hub’s support is free of charge, funded by the UK Government, and designed to make the UK a globally competitive destination for commercial clinical research. We provide: Single national entry to NIHR – One conversation provides access to our entire integrated commercial trials pathway. Dedicated operational leadership – A named national lead coordinates delivery and manages dependencies across the system. Reliable, data-enabled feasibility – Coordinated once, using real-time capability and capacity to improve predictability. Smarter site selection – Intelligent study placement across health and care settings for speed, quality and performance. Faster start-up – Coordinated oversight of costing, contracting and assurance. Active performance management and escalation – Real-time oversight of set-up and recruitment, with clear escalation routes and time-bound resolution. Inclusive, scalable recruitment – Approaches that improve reach, diversity and reliability, including digitally-enabled and hybrid delivery models. Strategic partnership opportunities – Portfolio-level engagement and longer-term collaboration with the NIHR research system.
Richmond Pharmacology
Richmond Pharmacology is a leading UK-based contract research organisation (CRO) providing comprehensive clinical research services from First-in-Human (FIH) and First-in-Patient (FIP) through to Phase III studies. For over two decades, we have partnered with pharmaceutical and biotechnology companies globally — particularly across the United States, Europe, and Japan — to deliver faster answers and empower smarter development decisions. Operating from a state-of-the-art clinical pharmacology unit in London, we integrate real-world clinical expertise, regulatory foresight, and operational excellence to support the successful delivery of complex clinical development programmes. Faster Answers for Smarter Decisions At Richmond Pharmacology, “Faster Answers” is our guiding principle. Through a combination of expert-led study design, agile operational models, and strategic regulatory insight, we enable sponsors to generate high-quality data earlier, accelerating programme timelines and reducing development risk. Our Core Expertise Includes: First-in-Human (FIH), First-in-Patient (FIP), and Clinical Development up to Phase III: Extensive experience managing trials from initial dosing through proof-of-concept and pivotal Phase III studies, across a broad range of therapeutic areas. Gene Editing and Gene Silencing Studies: Richmond Pharmacology is proud to support cutting-edge research in advanced therapeutic modalities, including CRISPR-Cas9 genome editing and RNA interference (RNAi)-based gene silencing, helping innovators bring transformative medicines to patients faster. Patient and Healthy Volunteer Studies: Our work spans both healthy volunteer and patient-focused research, with a strategic emphasis towards increasing patient-centric trials to better reflect real-world treatment needs. Rare and Orphan Disease Trials: We are recognised for our ability to design and conduct trials for rare and ultra-rare conditions, navigating recruitment and operational complexities with sensitivity and precision. Bridging Studies: Richmond Pharmacology is a leader in Japanese–European bridging studies, providing critical data to support global strategies. Cardiovascular, Metabolic, and Central Nervous System (CNS) Disorders: Specialist expertise in diseases such as cardiovascular disease (CVD), chronic kidney disease (CKD), hyperlipidaemia, non-alcoholic steatohepatitis (NASH), diabetes, and neurodegenerative or psychiatric disorders. Complex and Adaptive Trial Designs: Expertise in designing seamless adaptive protocols, umbrella trials, and novel methodologies that optimise development pathways while preserving scientific and regulatory integrity. Patient and Public Involvement (PPI): We embed Patient and Public Involvement across study planning and execution, ensuring trial designs are informed by patient perspectives to enhance engagement, experience, and outcomes. Regulatory Strategy and Scientific Consultancy: Richmond Pharmacology provides scientific and regulatory consultancy services, guiding sponsors through regulatory interactions and optimising study designs for approvals in the UK, US, and Europe. Why Partner with Richmond Pharmacology? Our experienced team, operational flexibility, and focus on scientific excellence make Richmond Pharmacology a trusted partner for companies seeking faster, smarter clinical development. Whether advancing a novel genetic therapy, accelerating a rare disease treatment, or bridging critical data across regions, we provide the solutions needed to move innovative therapies forward. For more information, please visit www.richmondpharmacology.com
Profil GmbH
Profil is the world’s leading CRO in metabolic research. As a full-service provider, we conduct early phase clinical trials within the indications of obesity, (pre)diabetes, and diabetes complications. We offer an unrivaled combination of science and professional conduct. This unique combination allows us to design and carry out best-in-class clinical trials for our clients. Our in-house scientific expertise covers pharmacology, obesity and prediabetes, nutritional sciences, cardiometbolic research, hepatology, endocrinology, the entire spectrum of diabetes complications, cell and molecular biology as well as metabolic monitoring and medical technology. One of our core technologies is the hyperinsulinemic euglycemic clamp, used to address action profiles of insulin and insulin analogues, beta cell function and insulin sensitivity. To address human metabolic pathways glucose clamp studies are combined with isotope dilution techniques and tissue biopsies. To be able to offer the best services for any glucose clamping setup, we have developed ClampArt, the next generation of glucose clamping. By owning a continuously updated database with entries of more than 30.000 well characterized individuals (healthy, healthy at-risk, type 1 and type 2 diabetes), we can recruit even the most complex clinical trials. We have a fully GMP certified pharmacy and in-house clinics with 60 beds and holds expertise in Data Management & Statistics and Regulatory Affairs.
Phase Clinical Services
Your complete resource for oncology clinical trials and biospecimens | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies. Our clients are pharma and biotech companies from startup to the top-ten level, assay developers, high-end academic institutions, and the U.S. government. We maintain an FDA-registered cell isolation lab in Milwaukee and an in-house pathology service. | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies.
Pharmtrace Klinische Entwicklung GmbH
pharmtrace is an independent CRO providing strategies and solutions for clinical trials. pharmtrace offers flexible services and a global reach for studies with imaging endpoints, radiopharmaceuticals, and radiological interventional procedures. pharmtrace’s experienced team and international medical specialists network ensure that your investment in medical imaging, radiopharmaceuticals and radiological interventions delivers meaningful data. With our GCP compliant image management platform (ERICA) we support you to generate robust data to convince authorities and decision makers, and to achieve your development target. pharmtrace’s customers include biotech and academia, as well as internationally engaged pharmaceutical companies and device manufacturers. | Full-service clinical trial management by a team that understands imaging and radiopharmaceuticals as deeply as clinical operations. pharmtrace is a private, independent contract research organisation for the pharmaceutical and medical device industry. We focus on clinical studies where diagnostic imaging and/or nuclear medicine approaches are a major component for efficacy or safety assessment — including RECIST-based oncology trials, therapeutic radiopharmaceutical programmes, and medical device investigations. Our clients are global pharmaceutical companies, biotech firms, and academic sponsors across North America, Europe, and Australasia. We have managed clinical trials across oncology, neurology, cardiology, and other therapeutic areas — from first-in-human exploratory studies through Phase 3 registration trials and Phase 4 post-marketing commitments. In each, imaging expertise was built in from the protocol stage, not retrofitted. Our experience includes studies that have supported marketing authorisation applications to FDA and EMA. We know what these submissions require and design our processes accordingly from the outset. pharmtrace’s Imaging Core Lab provides comprehensive support for all imaging aspects of clinical trials and medical device investigations. Whether your study applies RECIST 1.1 or iRECIST for tumour response in oncology, PERCIST for PET-based assessment, quantitative MRI endpoints in neurology, SPECT imaging in cardiology, or quantitative imaging for a medical device investigation — we standardise, collect, quality-control, and independently review images with the rigour that regulatory submissions require. Our proprietary ERICA platform, validated to GAMP5 Category 5, serves as the single environment for DICOM image storage, technical and medical QC, and blinded read sessions — with per-study configuration validation for every project. We support sponsors at any stage — from early imaging strategy and endpoint selection through regulatory meeting preparation and marketing authorisation support. Our advice is grounded in operational experience, not theory.
Orbis Clinical Life Sciences Solutions
Orbis Clinical is a leading global recruiting partner to the life sciences industry; we have been driving the success of our clients, consultants, and employees in staffing and consulting services since 2004. We provide multiple solutions spanning permanent and temporary placement to clients ranging from venture-backed start-ups through Fortune 500 firms. Our mission is to provide the world’s leading life science companies with expertise essential to treating devastating diseases.